NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®)

Colon Cancer

Overall management of Colon Cancer from diagnosis through recurrence is described in the full NCCN Guidelines® for Colon Cancer. Visit NCCN.org to view the complete library of NCCN Guidelines.

Reproduced with permission from the NCCN Guidelines for Colon Cancer V.2.2019. © 2019 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE

SUBSEQUENT THERAPY

**Previous oxaliplatin-based therapy without irinotecan**

- FOLFIRI\(^{\text{a}}\) or irinotecan\(^{\text{e}}\)
  - or FOLFIRI\(^{\text{a}}\) + (bevacizumab\(^{\text{k}}\) [preferred] or ziv-aflibercept\(^{\text{i,j}}\) or ramucirumab\(^{\text{k}}\))
  - or Irinotecan\(^{\text{e}}\) + (bevacizumab\(^{\text{k}}\) [preferred] or ziv-aflibercept\(^{\text{i,j}}\) or ramucirumab\(^{\text{k}}\))
  - or FOLFIRI\(^{\text{a}}\) + (cetuximab or panitumumab)\(^{\text{c,m,n}}\)
    - (KRAS/NRAS/BRAF WT only)
    - or Irinotecan\(^{\text{e}}\) + (cetuximab or panitumumab)\(^{\text{c,m,n}}\)
      - (KRAS/NRAS/BRAF WT only)
      - or Irinotecan\(^{\text{e}}\) + (cetuximab or panitumumab)\(^{\text{c,m}}\)
        - vemurafenib (BRAF V600E mutation positive)
        - or Dabrafenib + trametinib + (cetuximab or panitumumab)\(^{\text{c,m}}\)
          - (BRAF V600E mutation positive)
          - or Encorafenib + binimetinib + (cetuximab or panitumumab)\(^{\text{c,m}}\)
            - (BRAF V600E mutation positive)
            - or ([Nivolumab ± ipilimumab] or pembrolizumab)\(^{\text{o}}\)
              - (dMMR/MSI-H only)\(^{\text{c,g}}\)
              - or [Trastuzumab + [pertuzumab or lapatinib]]\(^{\text{p}}\)
                - (HER2-amplified and RAS wild-type) (category 2B)

**See Subsequent therapy**

- Irinotecan\(^{\text{e}}\) + (cetuximab or panitumumab)\(^{\text{c,m,n}}\)
  - (KRAS/NRAS/BRAF WT only)
  - or Regorafenib\(^{\text{q}}\)
    - or Trifluridine + tipiracil\(^{\text{q}}\)

- Regorafenib\(^{\text{q}}\)
  - or Trifluridine + tipiracil\(^{\text{q}}\)
  - or ([Nivolumab ± ipilimumab] or pembrolizumab)\(^{\text{o}}\)
    - (dMMR/MSI-H only)\(^{\text{c,g}}\)
    - or (Trastuzumab + [pertuzumab or lapatinib])\(^{\text{p}}\)
      - (HER2-amplified and RAS wild-type) (category 2B)
      - or [Trastuzumab + [pertuzumab or lapatinib]]\(^{\text{p}}\)
        - (HER2-amplified and RAS wild-type) (category 2B)

- See Subsequent therapy

- Regorafenib\(^{\text{q}}\)
  - or Trifluridine + tipiracil\(^{\text{q}}\)
  - or ([Nivolumab ± ipilimumab] or pembrolizumab)\(^{\text{o}}\)
    - (dMMR/MSI-H only)\(^{\text{c,g}}\)
    - or (Trastuzumab + [pertuzumab or lapatinib])\(^{\text{p}}\)
      - (HER2-amplified and RAS wild-type) (category 2B)
      - or Best supportive care

- See Subsequent therapy

See footnotes on COL-D (7 of 13)

---

1 Larotrectinib is a treatment option for patients with metastatic colorectal cancer that is NTRK gene fusion positive.

m If neither previously given

\(\text{o}\) If no previous treatment with a checkpoint inhibitor

p If no previous treatment with HER2 inhibitor.

r If not previously given

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE

SUBSEQUENT THERAPY

**FOLFOX or CAPEOX** or
FOLFOX + bevacizumab or
CAPEOX + bevacizumab or
FOLFOX + (cetuximab or panitumumab)(KRAS/NRAS/BRAF WT only) or
Irinotecan + (cetuximab or panitumumab)(KRAS/NRAS/BRAF WT only) or
Irinotecan + (cetuximab or panitumumab) + vemurafenib (BRAF V600E mutation positive) or
Dabrafenib + trametinib + (cetuximab or panitumumab)(BRAF V600E mutation positive) or
Encorafenib + binimetinib + (cetuximab or panitumumab)(BRAF V600E mutation positive) or
((Nivolumab ± ipilimumab) or pembrolizumab)(dMMR/MSI-H only) or
(Trastuzumab + [pertuzumab or lapatinib])(HER2-amplified and RAS WT) (category 2B) or
See Subsequent therapy

**Irinotecan + (cetuximab or panitumumab)**(KRAS/NRAS/BRAF WT only) or
Regorafenib or
Trifluridine + tipiracil or
((Nivolumab ± ipilimumab) or pembrolizumab)(dMMR/MSI-H only) or
(Trastuzumab + [pertuzumab or lapatinib])(HER2-amplified and RAS WT) (category 2B) or
See Subsequent therapy

**FOLFOX or CAPEOX** or
((Nivolumab ± ipilimumab) or pembrolizumab)(dMMR/MSI-H only) or
(Trastuzumab + [pertuzumab or lapatinib])(HER2-amplified and RAS WT) (category 2B) or
See Subsequent therapy

**See footnotes on COL-D (7 of 13)**

i Larotrectinib is a treatment option for patients with metastatic colorectal cancer that is NTRK gene fusion positive.

m If neither previously given

o If no previous treatment with a checkpoint inhibitor

p If no previous treatment with HER2 inhibitor.

r If not previously given

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Visit NCCN.org to view the complete library of NCCN Guidelines.
CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE

SUBSEQUENT THERAPY

Previous FOLFOXIRI

- Irinotecan\(^\text{a}\) + (cetuximab or panitumumab)\(^\text{c,n}\) (KRAS/NRAS/BRAF WT only) or
- Irinotecan\(^\text{a}\) + (cetuximab or panitumumab)\(^\text{c,m}\) + vemurafenib (BRAF V600E mutation positive) or
- Dabrafenib + trametinib + (cetuximab or panitumumab)\(^\text{c,m}\) (BRAF V600E mutation positive) or
- Encorafenib + binimetinib + (cetuximab or panitumumab)\(^\text{c,m}\) (BRAF V600E mutation positive) or
- Regorafenib\(^\text{q}\) or
- Trifluridine + tipiracil\(^\text{q}\)
- ([Nivolumab ± ipilimumab] or pembrolizumab)\(^\text{o}\) (dMMR/MSI-H only)\(^\text{c,g}\) or
- (Trastuzumab + [pertuzumab or lapatinib])\(^\text{p}\) (HER2-amplified and RAS WT) (category 2B)

- Regorafenib\(^\text{q,r}\) or
- Trifluridine + tipiracil\(^\text{q,r}\) or
- Best supportive care

See Subsequent therapy

\(^\text{a}\) Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

\(^\text{b}\) See footnotes on COL-D (7 of 13)

i Larotrectinib is a treatment option for patients with metastatic colorectal cancer that is NTRK gene fusion positive.

m If neither previously given

\(^\text{c}\) If no previous treatment with a checkpoint inhibitor

\(^\text{d}\) If no previous treatment with HER2 inhibitor.

\(^\text{r}\) If not previously given

\(^\text{r}\) See Subsequent therapy

© 2019 National Comprehensive Cancer Network